Stockscreener 앱 받기
31.91
6.46%
1.28
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Sutro Biopharma, Inc.(NasdaqGM:STRO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Index - marketscreener.com
Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (FWB:S090) - TradingView
STRO Forecast — Price Target — Prediction for 2027 - TradingView
S090 Forecast — Price Target — Prediction for 2027 - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090) - TradingView
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sutro Biopharma CSO Hans-Peter Gerber to join 2026 BIO International Convention panel - Traders Union
Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sutro Biopharma Inc (STRO) Institutional Confidence - TradingKey
Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sutro Biopharma Inc (STRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sutro Biopharma Inc (STRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sutro Biopharma Inc (STRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come - The Business Journals
Sutro Biopharma (STRO) Surges Over 9% as Buyers Test Key Resistance at $30.54Elliott Wave Entry - newsline.com
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities - Moomoo
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (STRO) Proxy filing Summary - Quartr
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director granted 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike - Stock Titan
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027 - Stock Titan
Sutro Biopharma (STRO) director receives 10,000-share stock option grant - Stock Titan
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Sutro Biopharma (STRO) director receives grant of 10,000 stock options - Stock Titan
Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant - Stock Titan
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results - Stock Titan
Sutro Biopharma Surges 5.52% – Testing Key Resistance at $30.11 After Strong SessionAdvance Decline Volume - newsline.com
Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings - Stock Titan
STRO Q1 2026 Earnings: Narrower Loss Beats Estimates as Sutro Biopharma Advances PipelineTech Earnings Analysis - The Legal Advocate
Barclays Initiates a Buy Rating on Sutro Biopharma (STRO) - The Globe and Mail
STRO Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target - marketscreener.com
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46% - simplywall.st
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts - Yahoo Finance
Barclays initiates Sutro Biopharma stock with overweight rating By Investing.com - Investing.com Australia
Barclays initiates Sutro Biopharma stock with overweight rating - Investing.com
Sutro Biopharma (STRO) Surges 6%: Key Levels and Market DynamicsEarnings Beat Stocks - The Legal Advocate
H.C. Wainwright Remains a Buy on Sutro Biopharma (STRO) - The Globe and Mail
STROSutro Biopharma Inc Stock Price and Quote - Finviz
H.C. Wainwright Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sutro Biopharma CEO unveils expanding ADC pipeline and key cancer partnerships - Traders Union
LifeSci Capital Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Sutro Biopharma (STRO) price target increased by 1,325.54% to 39.05 - MSN
Sutro Biopharma (STRO) Consolidates Near Resistance: Biotech Stock Shows Modest GainsSocial Trading Insights - Newser
1.16%
0.48%
자본화:
|
볼륨(24시간):